Regeneron Pharmaceuticals (REGN) : The money flow analysis of Regeneron Pharmaceuticals (REGN) indicates a $1.36 million of outflow was on downticks, whereas, the investors on Wednesday gobbled up stocks worth $4.21 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 3.1 and so was the total money flow at $2.85 million. The bulls lapped up $0.1 million worth of block trades on upticks. The money flow was $0.1 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of Regeneron Pharmaceuticals (REGN), pushing it down by -0.27% for the day. The stock slid $1.02 and traded at $376.14 during the day. Nonetheless, the stock is 0.62% over the previous weeks close.
Also, Bernstein initiates coverage on Regeneron Pharmaceuticals (NASDAQ:REGN) . Analysts at the Bernstein have a current rating of Outperform on the shares. The rating by the firm was issued on June 29, 2016.
Regeneron Pharmaceuticals (NASDAQ:REGN): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $377.48 and $375.44 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $386.97. The buying momentum continued till the end and the stock did not give up its gains. It closed at $384.70, notching a gain of 2.00% for the day. The total traded volume was 631,344 . The stock had closed at $377.15 on the previous day.
The stock has recorded a 20-day Moving Average of 6.74% and the 50-Day Moving Average is 2.78%. In a related news, The Securities and Exchange Commission has divulged that Ryan Arthur F, director of Regeneron Pharmaceuticals Inc, had unloaded 1,000 shares at an average price of $396.64 in a transaction dated on May 24, 2016. The total value of the transaction was worth $396,640.
Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Companys marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.